MedImmune Announces Winners of European Cancer Research Abstract Competition

CAMBRIDGE, England, November 4, 2010 - Today MedImmune announced the winners of its second annual European
research abstract competition which highlights the research of the next
generation of scientific leaders in cancer research. Students and
postdoctoral fellows from across Europe were invited to submit abstracts
describing their research in the field of tumour microenvironments as part of
the competition sponsored by MedImmune, AstraZeneca's global biologics unit,
which has a research facility in Cambridge, the United Kingdom.

Carmela De Santo a scientist from The Weatherall Institute of Molecular
Medicine, University of Oxford, UK, was awarded first prize of GBP2,000 for
her research in immune modulation entitled 'A novel melanoma immunoescape
mechanism based on the secretion of serum amyloid A and differentiation of
IL-10-secreting neutrophils'. "It is a great honour to win this competition
and to have the opportunity to present my research and gain feedback from
leading experts in oncology," said Carmela De Santo. "It is encouraging to
see a research-focused company recognizing young scientists and supporting us
in this way. I would like to thank MedImmune for this opportunity and
acknowledgement."

Second and third prizes of GBP1,000 and GBP500 were awarded to Alexandre
Trindade from the Faculty of Veterinary Medicine, Technical University of
Lisbon (UTL), Lisbon, Portugal and Gulbenkian Institute of Science, Oeiras,
Portugal for his research in angiogenesis, and Thomas Cox from The Institute
of Cancer Research, London, UK for his research in extracellular matrix
modulation respectively.

"We are extremely impressed with the caliber of the scientific research
being conducted by these researchers," said Dr Christian Blank, one of the
competition's judges and Group Leader, Immunology, The Netherlands Cancer
Institute, The Netherlands. "Increasing our understanding of tumour
microenvironments can help improve our overall understanding of how cancers
behave. The research these young scientists are conducting will add to the
pool of knowledge the scientific community can draw upon when developing new
therapies."

"One of our primary objectives at MedImmune is to promote and advance
health and science education," said Dr. Klaus Bosslet, Vice President
Research, Oncology, MedImmune. "This competition is part of our commitment to
investing in the development of the next generation of leading scientists.
These young scientists could one day occupy the top echelons of scientific
research and we at MedImmune are honored to play a part in their future
careers by providing some recognition for their hard work."

The competition was open to graduate students and postdoctoral fellows in
Europe with ten finalists shortlisted to present their research to an expert
panel of judges including Professor Adrian Harris, The Weatherall Institute
of Molecular Medicine, University of Oxford, UK; Dr. Christian Blank, Group
Leader, Immunology, The Netherlands Cancer Institute, The Netherlands; Dr.
Klaus Bosslet, Vice President Research, Oncology, MedImmune and Dr. Scott
Hammond, Scientist II, Senior Scientist, MedImmune. The focus of the
competition - tumour microenvironments - reflects the research interests of
MedImmune's UK-based Oncology Department in Cambridge. The three winners were
announced at the awards ceremony at Cambridge University's prestigious
Downing College following evaluation of their presentations on the basis of
scientific merit, innovation and delivery.

MedImmune

MedImmune, the worldwide biologics unit for AstraZeneca PLC (LSE: AZN.L,
NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered
in Gaithersburg, Maryland, USA. With an advancing pipeline of promising drug
candidates, MedImmune strives to deliver life-changing products, a rewarding
career to our employees and a tireless commitment to improving patient
health.

For more information, visit MedImmune's website at
www.medimmune.com.

Media Contacts: MedImmune, Perla Copernik, Phone: +1-240-388-5587 / +1-301-398-4952, Email: CopernikP at MedImmune.com. OgilvyHealthPR, Lucy Rispin, Phone: +44-(0)778-991-4901 / +44-(0)207108-6078, Email: lucy.rispin at ohpr.com